MedTrace Logo

The Influence of Lutein Supplements on Age-related Macular Degeneration

NCT01042860 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2010-01-08

No results posted yet for this study

Summary

Rationale: Age-related macular degeneration is the most common cause of blindness in the industrialized world. Macular pigment is hypothesized to protect against the vision loss in this disease.

Objective: 1. To study if the macular pigment optical density can be raised by lutein supplementation. 2. To study if lutein supplementation can stop or slow down the decrease in visual functions.

Study design: Randomized, double blind, placebo controlled intervention study.

Study population: Eighty patients with early signs of age-related macular degeneration Intervention: The intervention group (40 subjects) receives 10 mg lutein per day, while the control group (40 subjects) gets a placebo.

Conditions

  • Age-Related Macular Degeneration

Interventions

DIETARY_SUPPLEMENT

Lutein

Lutein supplement, 10 mg daily

DIETARY_SUPPLEMENT

Placebo

Placebo

Sponsors & Collaborators

  • Cognis Deutschland GmbH & Co. KG

    collaborator INDUSTRY

  • Maastricht University Medical Center

    lead OTHER

Principal Investigators

  • Tos TJM Berendschot, PhD · University Eye Clinic Maastricht

  • Ian J Murray, PhD · University of Manchester

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
FACTORIAL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01042860 on ClinicalTrials.gov